Historical record - last NADAC effective date: 1/3/2020

Product Information

ZORTRESS 0.75 MG TABLET is a brand product labeled by Novartis Pharmaceuticals Corporation, priced at $27.0419 per EA under NDC 00078041520. Its NADAC has been published 339 times since Jul 23, 2014.

FDA first approved this application on Apr 20, 2010. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

The High Outlier badge above means this manufacturer's average price in the everolimus market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.

ZORTRESS 0.75 MG TABLET

everolimus
$27.0419per EA
High Outlier

Strength

.75 mg/1

NDC

00078041520

Classification

Brand

Dosage Form

TABLET

Route

ORAL

Effective Date

1/3/2020

Active Ingredients

EVEROLIMUS

Approval Type

New Drug (NDA)

FDA Application

NDA021560

FDA Approved

4/20/2010

TE Code

AB

On Market Since

4/22/2010

Pharmacological Classes

Cytochrome P450 2D6 Inhibitors
Cytochrome P450 3A4 Inhibitors
Decreased Immunologic Activity
Kinase Inhibitor
Protein Kinase Inhibitors
mTOR Inhibitor Immunosuppressant
mTOR Inhibitors

Price Statistics

The NADAC for ZORTRESS 0.75 MG TABLET has been published 339 times since Jul 23, 2014, and over the history we have for it it has risen 40.0%. The table below summarizes its recorded NADAC range and movement.

Current price$27.0419 per EA
All-time high$27.0419 (Jan 13, 2021)
All-time low$19.3093 (Jul 23, 2014)
Median price$23.9517
Average price$23.6206
Largest weekly change+7.0% (Jul 15, 2015)
Weeks tracked339
Tracking sinceJul 23, 2014

Price History

1W

N/A

1M

N/A

3M

N/A

6M

N/A

1Y

N/A

3Y

N/A

5Y

N/A

All

+40.0%

Last surveyed Jan 13, 2021 — this NDC no longer appears in the current weekly NADAC file.

Generic Alternatives

The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 83% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Lowest-Cost Alternatives

Save up to 83%

1 alternative • Same active ingredient

Frequently asked questions

What is the NADAC price of ZORTRESS 0.75 MG TABLET?

The current National Average Drug Acquisition Cost (NADAC) for ZORTRESS 0.75 MG TABLET, manufactured by Novartis Pharmaceuticals Corporation, is $27.0419 per EA (NDC 00078041520), effective Jan 13, 2021.

How has the price of ZORTRESS 0.75 MG TABLET changed over time?

Over the history we have for it, the NADAC for ZORTRESS 0.75 MG TABLET has risen 40.0%. It has been tracked across 339 weekly CMS publications since Jul 23, 2014.

What are the highest and lowest recorded NADAC prices for ZORTRESS 0.75 MG TABLET?

Since Jul 23, 2014, the NADAC for ZORTRESS 0.75 MG TABLET has ranged from a low of $19.3093 (Jul 23, 2014) to a high of $27.0419 (Jan 13, 2021), with a median of $23.9517 per EA.

Are there cheaper alternatives to ZORTRESS 0.75 MG TABLET?

Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, EVEROLIMUS 0.75 MG TABLET, is $4.5722 per EA — about 83% below ZORTRESS 0.75 MG TABLET.

Who manufactures ZORTRESS 0.75 MG TABLET?

ZORTRESS 0.75 MG TABLET (NDC 00078041520) is labeled by Novartis Pharmaceuticals Corporation, and CMS classifies it as a brand product.